Skip to main content

Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production (2020)
Journal Article
Atkinson, S. K., Morice, A. H., & Sadofsky, L. R. (2020). Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production. ERJ Open Research, 6(4), https://doi.org/10.1183/23120541.00159-2020

Human rhinovirus (RV) is the most common cause of upper respiratory tract infection (URTI) and chronic airway disease exacerbation. Cough is present in 50–80% of URTI cases, accompanied by heightened airway hypersensitivity, yet no effective treatmen... Read More about Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production.

Azithromycin for sarcoidosis cough: an open label exploratory clinical trial (2020)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., …Hart, S. P. (in press). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, https://doi.org/10.1183/23120541.00534-2020

Background Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis a... Read More about Azithromycin for sarcoidosis cough: an open label exploratory clinical trial.

Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial (2020)
Journal Article
Smith, J. A., Kitt, M. M., Morice, A. H., Birring, S. S., McGarvey, L. P., Sher, M. R., …Ford, A. P. (in press). Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial. The lancet. Respiratory medicine, https://doi.org/10.1016/S2213-2600%2819%2930471-0

Background: Gefapixant is a P2X3 receptor antagonist in development for treatment of refractory (RCC) and unexplained chronic cough (UCC). Methods: We conducted a 12-week, Phase 2b, randomized, double-blind, placebo-controlled study in patients w... Read More about Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial.

Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility) (2020)
Journal Article
Higginson, I., Wilcock, A., Johnson, M., Bajwah, S., Currow, D., Lovell, N., …Brown, S. (2020). Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility). Thorax, https://doi.org/10.1136/thoraxjnl-2019-213879

New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3. Sixty-four patients w... Read More about Randomised, double-blind, multi-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility).


;